Our findings showed that the 5-LO inhibitor, Zi, modulates local and systemic immune responses, restrains pulmonary inflammation, ameliorates clinical disease, and enhances survival rates without interfering with the host’s ability to deal with MHV-3 and betacoronavirus-induced SARS-CoV-2 infections. This evidence concerns the gene ALOX5 and inflammation.